-
GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
GeoVax to Host Conference Call at 4:30 PM ET Atlanta, GA, May 7, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology…
-
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
Presentation Made During the 24th Annual World Vaccine Congress Atlanta, GA, April 4, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing…
-
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
Atlanta, GA, March 28, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today…
-
GeoVax to Present at the 36th Annual Roth Conference
ATLANTA, GA, March 12, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced…
-
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines Atlanta, GA, March 6, 2024 – GeoVax Labs, Inc.…
-
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
Progress across the pipeline in multiple clinical trials, including Phase 2 program of GEO-CM04S1, next-generation Covid-19 vaccine, and multicenter Phase 1/2 study of…
-
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
GeoVax to Host Conference Call at 4:30 PM ET Atlanta, GA, February 22, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology…
-
GeoVax to Present at the 2024 BIO CEO & Investor Conference
ATLANTA, GA, February 19, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced…
-
GeoVax Announces Multiple Patent Issuances and Allowances
Intellectual Property Assets Strengthened for Cancer Immunotherapy Program and for Marburg Virus and HIV Vaccines Atlanta, GA, February 13, 2024 – GeoVax Labs,…
-
GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants Atlanta, GA, February 6, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company…
-
Strengthening America’s Biosecurity: GeoVax Advances Domestic Vaccine Capability
Addressing Critical U.S. Vulnerabilities in Vaccine Supply and National Preparedness ATLANTA, GA, January 29, 2025 — GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology…
-
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
Atlanta, GA, January 29, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today…